604 related articles for article (PubMed ID: 25628308)
1. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Sandhu RK; Hohnloser SH; Pfeffer MA; Yuan F; Hart RG; Yusuf S; Connolly SJ; McAlister FA; Healey JS
Stroke; 2015 Mar; 46(3):667-72. PubMed ID: 25628308
[TBL] [Abstract][Full Text] [Related]
2. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
; Connolly S; Pogue J; Hart R; Pfeffer M; Hohnloser S; Chrolavicius S; Pfeffer M; Hohnloser S; Yusuf S
Lancet; 2006 Jun; 367(9526):1903-12. PubMed ID: 16765759
[TBL] [Abstract][Full Text] [Related]
3. Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.
Ather S; Shendre A; Beasley TM; Brown T; Hill CE; Prabhu SD; Limdi NA
Am J Cardiol; 2016 Jul; 118(2):232-6. PubMed ID: 27241839
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial.
McMurray JJ; Ezekowitz JA; Lewis BS; Gersh BJ; van Diepen S; Amerena J; Bartunek J; Commerford P; Oh BH; Harjola VP; Al-Khatib SM; Hanna M; Alexander JH; Lopes RD; Wojdyla DM; Wallentin L; Granger CB;
Circ Heart Fail; 2013 May; 6(3):451-60. PubMed ID: 23575255
[TBL] [Abstract][Full Text] [Related]
5. Left Ventricular Ejection Fraction and Clinically Defined Heart Failure to Predict 90-Day Functional Outcome After Ischemic Stroke.
Li Y; Fitzgibbons TP; McManus DD; Goddeau RP; Silver B; Henninger N
J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):371-380. PubMed ID: 30396839
[TBL] [Abstract][Full Text] [Related]
6. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ;
J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454
[TBL] [Abstract][Full Text] [Related]
7. Stroke and Systemic Embolism and Other Adverse Outcomes of Heart Failure With Preserved and Reduced Ejection Fraction in Patients With Atrial Fibrillation (from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF]).
Chung S; Kim TH; Uhm JS; Cha MJ; Lee JM; Park J; Park JK; Kang KW; Kim J; Park HW; Choi EK; Kim JB; Kim CS; Lee YS; Shim J; Joung B
Am J Cardiol; 2020 Jan; 125(1):68-75. PubMed ID: 31699363
[TBL] [Abstract][Full Text] [Related]
8. [Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Meinertz T
Internist (Berl); 2007 Aug; 48(8):874-5. PubMed ID: 17628764
[No Abstract] [Full Text] [Related]
9. Real-world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center.
Tseng AS; William Schleifer J; Shen WK; McBane R; Mankad S; Esser H; Vucicevic D; Shamoun FE
Clin Cardiol; 2017 Dec; 40(12):1328-1332. PubMed ID: 29247519
[TBL] [Abstract][Full Text] [Related]
10. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction.
Badheka AO; Rathod A; Kizilbash MA; Bhardwaj A; Ali O; Afonso L; Jacob S
Am J Cardiol; 2011 Nov; 108(9):1283-8. PubMed ID: 21855829
[TBL] [Abstract][Full Text] [Related]
12. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project.
Banerjee A; Taillandier S; Olesen JB; Lane DA; Lallemand B; Lip GY; Fauchier L
Eur J Heart Fail; 2012 Mar; 14(3):295-301. PubMed ID: 22294759
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan in patients with atrial fibrillation.
; Yusuf S; Healey JS; Pogue J; Chrolavicius S; Flather M; Hart RG; Hohnloser SH; Joyner CD; Pfeffer MA; Connolly SJ
N Engl J Med; 2011 Mar; 364(10):928-38. PubMed ID: 21388310
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Lam CS; Carson PE; Anand IS; Rector TS; Kuskowski M; Komajda M; McKelvie RS; McMurray JJ; Zile MR; Massie BM; Kitzman DW
Circ Heart Fail; 2012 Sep; 5(5):571-8. PubMed ID: 22887722
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of atrial fibrillation and severity of symptoms of heart failure in patients with low gradient aortic stenosis and preserved left ventricular ejection fraction.
Moretti M; Fabris E; Morosin M; Merlo M; Barbati G; Pinamonti B; Gatti G; Pappalardo A; Sinagra G
Am J Cardiol; 2014 Dec; 114(11):1722-8. PubMed ID: 25316349
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry.
Schnabel RB; Ameri P; Siller-Matula JM; Diemberger I; Gwechenberger M; Pecen L; Manu MC; Souza J; De Caterina R; Kirchhof P
Europace; 2023 Aug; 25(9):. PubMed ID: 37713182
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
Cannon JA; Shen L; Jhund PS; Anand IS; Komajda M; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2016 Aug; 18(8):1021-31. PubMed ID: 27194023
[TBL] [Abstract][Full Text] [Related]
19. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators.
JAMA; 1998 Apr 22-29; 279(16):1273-7. PubMed ID: 9565007
[TBL] [Abstract][Full Text] [Related]
20. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
